NCG Mouse Details
NCG mice are triple immunodeficient and lack functional/mature T, B, and NK cells, and have reduced macrophage and dendritic cell function. These animal models have the ability to host xenograft cells, tissue, and human immune system components. The characteristics of NCG mouse models make them ideal for research on immuno-oncology, tumor biology, infectious disease, graft-versus-host disease (GvHD), hematopoiesis, and tissue transplant studies.
The NCG mouse is the foundation for the Charles River Hu-Mouse™ portfolio.
Co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to Charles River in 2016. The NCG mouse model was created by sequential CRISPR/Cas9* editing of the Prkdc and Il2rg loci in the NOD/Nju mouse, generating a mouse coisogenic to the NOD/Nju.
The NOD/Nju carries a mutation in the Sirpa (SIRP α) gene that allows for engrafting of foreign hematopoietic stem cells. The Prkdc knockout generates a SCID-like phenotype lacking proper T-cell and B-cell formation. The knockout of the Il2rg gene further exacerbates the SCID-like phenotype while additionally resulting in a decrease of NK cell production. This mouse model is ideal for oncology, immunology, infectious disease, graft-versus-host disease (GvHD), diabetes, regenerative medicine, and human organ transplantation. The NCG mouse model can also be utilized to create humanized mice by engrafting PBMCs or CD34 stem cells to closely mimic the human immune system.
Note: NCG mice available in North America only.
See our isolator page for available immunocompromised animal housing units.
**CRISPR/CAS9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.
Download the Report
Download the Report
- Technical Information
- The single mouse trial format predicts the sensitivity towards checkpoint
- Evaluation of in vivo anti-tumor response of solid tumors in a novel immune cell humanized NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl mouse model
- Combination Immune Checkpoint Inhibitors for the Treatment of Human Colon Carcinoma in hPBMC-NCG Humanized Mouse Model
- Humane end point refinement for total body irradiation and humanization of NCG mice
- NCG/CRL as a novel (Charles River) humanized mouse model for pre-clinical oncology studies: immunophenotypic characterization and performance monitoring
KRAS4A directly regulates hexokinase (Nature, 2019)
5-methylcytosine promotes pathogenesis of bladder cancer through stabilizing mRNAs (Nat Cell Biol, 2019)
HPN536, a T cell-engaging, Mesothelin/CD3-specific TriTAC for the treatment of solid tumors (Harpoon Therapeutics, 2018)
Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate (JCI Insight, 2018)
Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice (Molecular Therapy – Methods & Clinical Development, 2017)
Frequently Asked Questions (FAQs) about the NCG Mouse Model
How was the NCG mouse model created?
NCG mice were created using CRISPR/Cas9* technology.
*CRISPR/CAS9 used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.
What types of studies can NCG mice be used in?
These characteristics enable researchers to further study tumor biology and immuno-oncology, hematopoiesis, infectious disease, GvHD, and organ development and function because of their capability of hosting xenograft cells, tissue, and human immune system components.
- What types of NCG humanized mice are available?
How can I evaluate a NCG mouse model?
Our Animal Model Evaluation Program helps researchers find the most appropriate model for their studies.
Are NCG mice good for the creation of humanized mouse models?
The NCG mouse model is the foundation of our humanized mouse model portfolio. NCG mice have a unique phenotype that allows it to host xenograft cells, tissue, and components of the human immune systems. It displays noticeable improvements of foreign tissue transplantation and engraftment, compared to previous generations of immunocompromised mice.